NRXP | NRx Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2500 - 2.4919
52 Week Range	1.1000 - 7.33
Beta	1.47
Implied Volatility	258.09%
IV Rank	42.97%
Day's Volume	320,838
Average Volume	1,227,027
Shares Outstanding	15,700,400
Market Cap	35,796,912
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-12-04

Valuation
Profitability
Growth
Health
P/E Ratio	-1.08
Forward P/E Ratio	N/A
EPS	-2.11
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	2
Country	USA
Website	NRXP

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

NRXP's peers: LQDA, RLFFD, PHGE, LEXX, ADTX, NTRB, QNRX, LGVN, RNXT, VRAX, SABSW, SNTI, CING, BLCM, HILS, NRXPW

*Chart delayed

Analyzing fundamentals for NRXP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NRXP Fundamentals page.

Watching at NRXP technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NRXP Technicals page.